Workflow
CVS Health(CVS)
icon
Search documents
CVS Health(CVS) - 2022 Q2 - Earnings Call Transcript
2022-08-03 16:54
CVS Health Corporation (NYSE:CVS) Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Larry McGrath - Senior Vice President Business Development and Investor Relations | Karen Lynch - President and Chief Executive Officer Shawn Guertin - Executive Vice President and Chief Financial Officer Alan Lotvin - President, Pharmacy Services Dan Finke - President, Healthcare Benefits Michelle Peluso - Executive Vice President. Chief Customer Officer and Co-President, Retail Prem Shah - Exe ...
CVS Health(CVS) - 2022 Q2 - Quarterly Report
2022-08-03 10:35
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission File Number: 001-01011 ♥CVSHealth CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 05-04 ...
CVS Health(CVS) - 2022 Q1 - Earnings Call Transcript
2022-05-04 16:23
CVS Health Corporation (NYSE:CVS) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Tom Cowhey - Senior Vice President, Capital Markets Karen Lynch - President and Chief Executive Officer Shawn Guertin - Executive Vice President and Chief Financial Officer Jon Roberts - Executive Vice President and Chief Operating Officer Alan Lotvin - President, Pharmacy Services Dan Finke - President, Healthcare Benefits Conference Call Participants Lisa Gill - JPMorgan Ricky Goldwasser - Morgan ...
CVS Health(CVS) - 2022 Q1 - Quarterly Report
2022-05-04 10:35
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission File Number: 001-01011 CVSHealth CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 05-04 ...
CVS Health(CVS) - 2021 Q4 - Earnings Call Transcript
2022-02-10 06:00
Ladies and gentlemen, good morning and welcome to the CVS Health fourth quarter and full year 2021 earnings conference call. At this time, all participants are in a listen only mode. A question and answer session will follow CVS Health prepared remarks, at which point we will review instructions on how to ask your questions. As a reminder, today's conference is being recorded. I would now like to turn the call over to Susie Lisa, Senior Vice President of Investor Relations for CVS Health. Please go ahead. T ...
CVS Health(CVS) - 2021 Q4 - Annual Report
2022-02-09 11:37
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission file number: 001-01011 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 05-0494040 (State or ...